An Efficacy and Safety Comparison of Regorafenib and Nivolumab in Unresectable Hepatocellular Cancer Patients: A Systematic Review. ama [Internet]. 2024 Apr. 30 [cited 2025 Aug. 16];53(1):46-58. Available from: https://www.ama.ba/index.php/ama/article/view/564